ReviewFrontiers in neurology2026
Programmed cell death evasion in BRAF V600E-driven primary CNS tumors and thyroid cancer brain metastases.
Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BRAF V600E occurs in selected primary central nervous system (CNS) tumors and in a subset of thyroid cancers that can metastasize to the brain, but the shared alteration does not make these diseases biologically equivalent. This Mini Review examines programmed cell death evasion in pleomorphic xanthoastrocytoma and ganglioglioma, with selected molecular and clinical comparisons involving epithelioid glioblastoma, pilocytic astrocytoma, pediatric low-grade glioma, and thyroid cancer brain metastases (TCBM). Evidence linking BRAF-MEK-ERK signaling to apoptosis is strongest in non-CNS thyroid cancer and other BRAF-mutant models; direct validation in TCBM remains limited. Ferroptosis sensitization has been demonstrated preclinically in BRAF V600E anaplastic thyroid cancer outside the brain, whereas the ferroptosis suppressor protein 1 (FSP1)/coenzyme Q10 (CoQ10) axis and dihydroorotate dehydrogenase (DHODH) remain general mechanistic frameworks rather than established dependencies in the target CNS settings. Clinical studies support BRAF/MEK inhibition in BRAF V600E-mutant glioma and systemic anaplastic thyroid cancer, but direct TCBM intracranial evidence is restricted to very limited, confounded observations. The intact blood-brain barrier, heterogeneous blood-tumor barrier, efflux transporters, and brain microenvironment further complicate inference from systemic outcomes. We therefore separate direct, indirect, and hypothesis-generating evidence and identify disease-specific pharmacokinetic, mechanistic, and prospective clinical studies as priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.